Novartis and Roche’s long-running battle to try to prevent off-label prescribing of Roche’s Avastin in place of their approved Lucentis product for the eye disease age-related macular degeneration
Amgen's biosimilar version of Roche’s top selling cancer drug, Avastin has been approved in the US, making it the first ever cancer biosimilar approved by the FDA.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
